Email: cspc@cspc.cn
News
June 13, 2025
Share:
Previous: VOLUNTARY ANNOUNCEMENT - MELOXICAM INJECTION (III) OBTAINS DRUG REGISTRATION APPROVAL
Next: VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us